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doi:10.1016/j.ejvs.2009.11.040Abstract Objective: This study aims to compare the outcome 2 years after treatment of vari-
cose veins by endovenous laser ablation (EVLA) or surgery by assessing recurrence, venous clin-
ical severity score (VCSS) and quality of life.
Methods: A total of 121 patients (137 legs) were randomised to either EVLA or saphenofemoral
ligation and stripping of the great saphenous vein (GSV). Follow-up included clinical and duplex
ultrasound examinations, VCSS and quality of life questionnaires.
Results: A total of 18 (26%) and 25 patients (37%) in the EVLA and surgery group, respectively,
developed recurrent varicose veins (not significant (NS) between groups). The source of reflux
was not significantly different between the groups. Technical failure occurred in three EVLA
and two surgery patients, reflux in the anterior accessory GSV, the groin, thigh and calf perfo-
rators was found in six, two, four, and three EVLA patients, and in three, three, nine and six
surgery patients. VCSS, Aberdeen Varicose Vein Severity Score and several domains of the
Medical Outcomes Study Short Form 36 (SF36) quality of life score improved significantly in
both groups.
Conclusions: No significant differences in clinical or ultrasound recurrences were found
between EVLA and surgery groups. Our study also shows that similar improvements in clinical
severity scores and quality of life were gained in both treatments.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ting 3e6 September, 2009, European Society for Vascular Surgery, Oslo, Norway.
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In recent years, endovenous laser ablation (EVLA) of the
saphenous vein has gained popularity for the treatment of
patients with saphenous vein incompetence resulting in
varicose veins. Numerous reports have demonstrated a high
degree of safety and efficacy of EVLA with respect to
elimination of the incompetent vein, improvement in
symptoms and quality of life, as well as a high degree of
patient satisfaction with the treatment.1,2 Although
recently published randomised clinical trials did not show
major clinical differences in the short-term outcome of
EVLA and surgery, they suggested that recurrence rates and
pattern may differ in the longer term.3e6
Recurrent varicose veins after surgery are a frequent
problem, with recurrence rates ranging from 15 to 80%
after 5 years or more; however, recurrence after EVLA has
only been described to a limited extent.6,7 Most studies
have been non-randomised and have focussed on re-
canalisation of the great saphenous vein (GSV) rather than
on varicose vein recurrence. Proper clinical evaluation
with adequate follow-up in randomised trials is important
before conventional surgical treatment is replaced by EVLA
or other new endovascular methods. The present report
describes the outcome 2 years after treatment with either
EVLA or high ligation and stripping in a randomised clinical
trial. The study was approved by the Regional Ethics
Committee.
Patients and methods
The methodology and short-term outcome of this rando-
mised clinical trial have been fully described in a previous
publication.3 The study was conducted in two private
surgical centres which work under contract to the national
health-care system in Denmark. In brief, consecutive
patients, with symptomatic varicose veins and GSV
incompetence (clinical, etiologic, anatomic and patho-
physiologic (CEAP) C2e4EpAsPr) were randomised by sealed
envelopes to either surgery or EVLA. The preoperative
assessment, including CEAP grading and venous clinical
severity scoring (VCSS), was performed by one of two
vascular and general surgeons, with experience in the
management of venous disease. Bilateral treatment was
permitted, provided both limbs received the same treat-
ment during the same operation. Patients who had under-
gone previous saphenofemoral ligation were included in
the trial. Exclusion criteria were duplication of the
saphenous trunk or an incompetent anterior accessory GSV
(AAGSV), small saphenous or deep vein incompetence,
previous deep vein thrombosis, arterial insufficiency, or
a tortuous GSV rendering the vein unsuitable for endove-
nous treatment.
Treatment
All treatments were performed in a treatment room under
tumescent local anaesthesia using a solution of 0.1% lido-
caine with adrenaline and bicarbonate. Two experienced
surgeons from the two study centres performed all the
treatments and investigations.The surgical procedure was carried out through a 4- to 6-
cm incision in the groin, with flush division of the GSV and
division of all tributaries behind the second level of divi-
sion.8 The GSV was then removed using a pin-stripper to
just below the knee.
The EVL procedure was performed under duplex guid-
ance with a 980-nm diode laser (Ceralas D 980, Biolitec,
Bonn, Germany) using pulse mode and a power of 12 W. The
GSV was cannulated percutaneously just below the knee or
at the lowest point of reflux on the thigh. In two cases,
a small cut-down was performed. The laser fibre was
advanced until 1e2 cm below the saphenofemoral junction
after which the GSV was ablated during withdrawal of the
fibre. The mean (range) energy used was 73.5 (57e95)
joules cm1 GSV. All varicose veins were removed by
phlebectomy during the same procedure in both groups of
patients.
After the treatment, the leg was wrapped in sterile
absorbent bandages and covered with a cohesive
compression bandage for 48 h. The patients were instruc-
ted to wear a medical compression stocking (18 mmHg)
during the day for at least 2 weeks after the bandage was
removed.
Assessments
The patients attended follow-up at 12 days, and then after
1, 3 and 6 months and yearly thereafter. The present
report describes the findings 2 years after surgery. The
surgeon performed clinical and duplex ultrasound exami-
nations (DUSs) at all visits. The clinical examinations were
performed with the surgeon sitting in front of the standing
patient. Ultrasound examinations for reflux were per-
formed by manually compressing the calf with sudden
release. Reflux >0.5 s was considered pathological. A Hawk
ultrasound system (BK Medical, Denmark) was used for the
DUS examinations. The track of the treated GSV, the deep
veins and all axial veins were investigated with DUS for
visibility, compressibility, blood flow and reflux. VCSS, the
Aberdeen Varicose Vein Symptoms Severity Score (AVVSS)
and the Medical Outcomes Study Short Form 36 (SF36)
health-related quality of life score, were completed by the
patient and recorded by a research nurse.9e11 A statisti-
cian performed the calculations. Just before each clinical
investigation, the patients indicated, with a pen on the
AVVSS form, if they considered varicose veins to be
present. Subsequently, the surgeon would inspect the leg
for varicose veins and other signs of venous insufficiency.
In patients with evidence of varicose veins or signs of
venous insufficiency (C2 or higher) the source of reflux, if
possible, would be identified and categorised as reflux in
the groin, the GSV, AAGSV and perforators in the thigh
and/or calf.
Technical success was considered to have been achieved
when the GSV was closed or absent. A re-canalised GSV or
treatment failure was defined as an open section of the
treated vein segment >5 cm in length. The criterion for
a varicose vein was a visible or palpable varicosity with
a diameter of more than 3 mm. At follow-up, a varicose
vein, which had not been observed before or previously
been marked by the patient on the AVVSS form, was
considered to be a recurrent varicose vein.
Table 1 Baseline patient characteristics.
Surgery EVLA
No. of patients/legs 59/68 62/69
Age median (range) 54 (22e78) 53 (26e79)
Sex (F/M) 43/16 41/21
CEAP No. (%)
C2 51 (86) 50 (81)
C3 5 (8) 3 (5)
C4 3 (5) 9 (15)
Figure 1 KaplaneMeyer plot of recurrence during the first
2 years after treatment of varicose veins with either EVLA or
conventional surgery. pZ NS. Vertical axis: probability of
freedom from varices. Horizontal axis, months after treat-
ment. Legends: ddd surgery, eeeeee EVLA.
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The primary ultrasound end point was a closed or absent
GSV and the clinical end point was the appearance of new
varicose veins after surgery. A priori sample size calcula-
tions indicated, that to detect a 15% difference in closed or
absent GSV or recurrence rate between the groups with
aZ 5 and bZ 80, 60 legs would be needed in each group.
Efficacy end points AVVSS and SF36 score were analysed
using analysis of variance for repeated measurements. For
the VCSS, intergroup comparisons were made by Manne
Whitney statistics and intra-group comparisons by Friedman
statistics. The time to failure or appearance of new vari-
cose veins was analysed using log-rank statistics.
Results
A total of 121 consecutive patients (137 legs) gave written
informed consent for inclusion in this study between August
2005 and July 2006 and were randomised to the surgical and
EVLA groups. The groups were comparable with respect to
patient characteristics and CEAP classification of treated
legs (Table 1). There were two technical failures in the
surgery group where the GSV broke during stripping. It was
not possible to extract the remaining part of those veins
through a distal incision because the stripper could not pass
through the partially invaginated vein. In the EVLA group,Table 2 Comparison of cumulative recurrence rates and







Clinical recurrence (%) 25/68 (37) 18/69 (26) 0.20
Observed by patient (%) 9/68 (13) 8/69 (12) 0.80
Not seen at follow-up (%) 10/68 (15) 4/69 (6) 0.10
Technical failure (%) 2 (3) 3 (4) 1.00
Reflux into the AAGSV* (%) 3 (4) 6 (8) 0.49
Reflux in the groin (%) 3 (4) 2 (3) 0.68
Reflux in thigh
perforators (%)
9 (13) 4 (6) 0.16
Reflux in lower leg
perforators (%)
6 (9) 3 (4) 0.33
AAGSV*, anterior accessory great saphenous vein.three GSVs completely re-canalised within the first
6 months. The lengths (diameters) of the GSVs that re-
canalised were 25 cm (1.2 cm), 32 cm (0.7 cm) and 30 cm
(1 cm), respectively. The laser energy in those GSVs was 61,
78 and 70 joules cm1 vein, respectively. Such character-
istics were not significantly different from the remaining
veins. They were all retreated with foam sclerotherapy,
considered to be treatment failures and were removed
from the study. No GSVs were re-canalised thereafter. No
clinically relevant differences between the groups were
found within the first 6 postoperative months.3
The incidence of clinical recurrence increased gradually
from 6 months onward. At 2 years follow-up, clinical
recurrence was found in 25 (37%) and 18 legs (26%) in the
surgery and EVLA groups, respectively (not significant (NS),
Table 2). Six patients in the surgery group and nine in the
EVLA group were retreated, mostly for cosmetic reasons.
However, in only nine (13%) legs in the surgery group and
eight legs (12%) in the EVLA group had the recurrence been
observed by the patient. No significant difference in quality
of life could be measured in patients with and without
recurrence. Reflux developed in the anterior accessory GSV
in three legs following surgery and six legs after EVLA (NS).
Reflux after surgery was found in the groin (three legs), the
thigh (nine legs) and the calf (six legs), respectively. InFigure 2 VCSS in patients treated with EVLA or surgery. No
significant difference between groups. For improvement over
time p < 0.01. Legends: ddd surgery, eeeeee EVLA. Error
bars: mean  2 standard deviations. Abbreviations: VCSS,
venous clinical symptoms score; Mth, months.
Figure 3 Aberdeen varicose veins severity score in patients treated with EVLA or surgery. No significant difference between
groups. For improvement over time p < 0.01. Legends:ddd surgery, eeeeee EVLA. Error bars: mean  2 standard deviations.
Abbreviations: Mth, months after treatment.
EVLA versus Conventional Surgery for Varicose Veins 633comparison, in the EVLA group, reflux was found in the
groin (two legs), the thigh (four legs) and the calf (three
legs) (NS). A KaplaneMeier plot of recurrence over time is
shown in Fig. 1. There was no difference between groups.
Improvements in both groups in the clinical scoring and
quality of life measures were observed from 3 months
onwards (p < 0.01). For the SF36 scores, improvements
were seen in the domains bodily pain, vitality and social
functioning (p < 0.01). The improvement in VCSS and
quality of life scores were still present after 2 years (Figs.
2e6).Discussion
The recurrence of varicose veins and reflux were not
significantly different between the groups. However,
recurrence among our patients was substantially higher
than in a recent study, where only 6.6 and 7% of legs had
developed new varicose veins 2 years after surgery and
EVLA, respectively.6 In both studies, varices noticed by the
patient or the surgeons were counted, and apparently the
same criteria for evaluation were used. We have no clear
explanation for such discrepancy. The fact that some of theFigure 4 SF36 health-related quality of life score in patients tre
difference between groups. For improvement over time p < 0.01. L
standard deviations.varices classified as recurrent in our study might have been
residual may have influenced the results however. In
another randomised clinical trial, recurrence was found in
23 and 34% of patients for up to 2 years after EVLA or cry-
ostripping, respectively.7 In two other studies, clinical
recurrence was found in 25 and 51% of patients, respec-
tively, 5 years after conventional surgery.12,13 This differs
little from our results. Technical failure occurred in two
and three of our patients in the surgery and EVLA groups,
respectively. Failures due to technical problems, where the
GSV breaks during stripping are not uncommon.12,13 Simi-
larly, early re-canalisation after EVLA may happen, but
most cases can be avoided if the laser energy used for
ablation is more than 80 joules cm1 of GSV.14 In addition,
using the laser in continuous mode instead of pulse mode
might reduce re-canalisation.
The primary causes of recurrence after surgery are
tactical errors, technical errors, neo-vascularisation and
progression of the disease.15 Tactical errors, where the
source of reflux is anatomically misjudged, will probably
have minor importance when DUS is used preoperatively as
in our patients. Only two studies have previously detailed
the distribution of reflux after EVLA compared to surgery.6,7
Two years after conventional surgery, in the study byated with EVLA or surgery, domain bodily pain. No significant
egends: ddd surgery, eeeeee EVLA. Error bars: mean  2
Figure 5 SF36 health-related quality of life score in patients
treated with EVLA or surgery: domain vitality. No significant
difference between groups. For improvement over time
p < 0.01. Legends:ddd surgery, eeeeee EVLA. Error bars:
mean  2 standard deviations.
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vascularisation in the groin in two cases (3%) and mid-thigh
perforator reflux in another two cases. After EVLA, re-
canalisation was the cause in three patients (4%), mid-thigh
perforator reflux in one (1%) and a refluxing AAGSV the
cause in another patient.6 In the study by Disselhoff et al.,
the pattern of recurrence was similar to ours.7 The distri-
bution of reflux in our patients with new varicose veins was
not statistically different between the groups. Reflux into
the AAGSV accounted for a substantial number of recur-
rences. We do not believe that tactical or technical errors
were the cause of reflux in these cases, since it developed
after the first 6 months. Accordingly, reflux in six AAGSVs
after EVLA probably indicates disease progression, whereas
in the three cases in the surgical group, neo-vascularisation
must also play a role. The relatively high incidence of late
reflux in the AAGSV in our patients may make it worthwhile
considering primary ablation of this vein if possible, even if
it is competent. However, some authors have suggested
avoiding ablation of this vein at the initial operation.7,16
Alternatively, it can be treated easily with ultrasound-
guided foam sclerotherapy at a later stage should it
become incompetent resulting in the development of
varices. Reflux in the groin and in thigh perforators in our
patients was probably caused by neo-vascularisation or
disease progression, since the GSV had been completely
ablated in these patients. Reflux in calf perforators mayFigure 6 SF36 health-related quality of life score in patients
treated with EVLA or surgery: domain social functioning. No
significant difference between groups. For improvement over
time p < 0.01. Legends:ddd surgery, eeeeee EVLA. Error
bars: mean  2 standard deviations.have been present initially, since we did not exclude
patients with incompetent perforators. Neither did we
record them preoperatively. It is possible that ablation of
an incompetent GSV in the calf as well in the thigh may
influence recurrence after EVLA.
The recurrence of varicose veins in our patients was
mostly minor, in many cases not noticed by the patient, and
was not associated with a significant increase in mean VCSS.
The disease-specific quality of life (AVVSS) remained simi-
larly improved. The same was true for several domains of
SF36. Such improvements after treatment of primary vari-
cose veins with surgery, EVLA and radio-frequency ablation,
have been demonstrated before, confirming that treatment
of primary varicose veins is worthwhile.3e5,17e19 The
present study is the first to demonstrate in a randomised
trial that improvement in quality of life after EVLA is pro-
longed beyond the first 6 months following treatment. This
prolonged improvement in quality of life was the same in
both treatment groups.
One shortcoming of the present study is the fact, that
for practical reasons, the treatment and follow-up exami-
nations were not blinded. The patient completed the
quality of life questionnaires however, including drawing of
varices on the AVVSS form. Ideally, studies such as the
present should be blinded as much as possible, and it is
technically possible to blind the observer at follow-up, but
not the patient. Another shortcoming of the study is our
recording of recurrent varicose veins after surgery. This was
not formally performed according to the recurrent varices
after surgery (REVAS) classification, which is thought to be
a useful tool when comparing different studies and treat-
ments.20 However, our classification of the recurrent vari-
ces follows the definitions of REVAS and presents most of
the information. The present study was powered to show
a 15% difference in success rate. Because such difference
was not demonstrated, there is a 20% risk of a type 2 error.
In our opinion, the present study represents a robust
comparison of the two treatments.
In conclusion, our study showed no difference in recur-
rence and reflux after EVLA compared to conventional
surgery in the treatment of primary varicose veins. Our
results have shown that the improvement in quality of life
gained from the minimally invasive EVLA is the same as that
achieved by conventional surgery. The choice of treatment
should be tailored to each individual patient taking into
account factors such as the anatomy of the veins, the
patient’s wishes, economy and the surgeon’s preferences.
Future studies should include more patients if possible, and
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